What is Karyopharm Therapeutics Inc.'s Market Cap?

Karyopharm Therapeutics Inc.'s Market Cap is $39.0M, based on as-reported figures from SEC (XBRL) filings.

What is Karyopharm Therapeutics Inc.'s Price / Sales?

Karyopharm Therapeutics Inc.'s Price / Sales is 0.3×, based on as-reported figures from SEC (XBRL) filings.

What is Karyopharm Therapeutics Inc.'s Revenue (TTM)?

Karyopharm Therapeutics Inc.'s Revenue (TTM) is $146.6M, based on as-reported figures from SEC (XBRL) filings.

What is Karyopharm Therapeutics Inc.'s Net Income (TTM)?

Karyopharm Therapeutics Inc.'s Net Income (TTM) is -$224.7M, based on as-reported figures from SEC (XBRL) filings.

What is Karyopharm Therapeutics Inc.'s EBITDA?

Karyopharm Therapeutics Inc.'s EBITDA is -$82.2M, based on as-reported figures from SEC (XBRL) filings.

What is Karyopharm Therapeutics Inc.'s Diluted EPS (TTM)?

Karyopharm Therapeutics Inc.'s Diluted EPS (TTM) is -9.91, based on as-reported figures from SEC (XBRL) filings.

What is Karyopharm Therapeutics Inc.'s EBITDA Margin?

Karyopharm Therapeutics Inc.'s EBITDA Margin is -56.1%, based on as-reported figures from SEC (XBRL) filings.

Karyopharm Therapeutics Inc. (KPTI) Financial Statements

Karyopharm Therapeutics Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001V0G6X5

XNAS · usd

1.72▼ 0.07 (-3.91%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value—

Trailing P/E—

Price / Sales

EV / Revenue—

EV / EBITDA—

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt—

Trading Information

Previous Close1.79

Day's Range1.70 – 1.79

52-Week Range1.70 – 10.99

Volume1.0M

Avg Volume2.1M

Share Statistics

Shares Outstanding

Employees228

ExchangeXNAS

Listed2013-11-06

Share count as of August 6, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Karyopharm Therapeutics Inc. (KPTI)

What is Karyopharm Therapeutics Inc.'s Market Cap?: Karyopharm Therapeutics Inc.'s Market Cap is $39.0M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Price / Sales?: Karyopharm Therapeutics Inc.'s Price / Sales is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Revenue (TTM)?: Karyopharm Therapeutics Inc.'s Revenue (TTM) is $146.6M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Net Income (TTM)?: Karyopharm Therapeutics Inc.'s Net Income (TTM) is -$224.7M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s EBITDA?: Karyopharm Therapeutics Inc.'s EBITDA is -$82.2M, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s Diluted EPS (TTM)?: Karyopharm Therapeutics Inc.'s Diluted EPS (TTM) is -9.91, based on as-reported figures from SEC (XBRL) filings.
What is Karyopharm Therapeutics Inc.'s EBITDA Margin?: Karyopharm Therapeutics Inc.'s EBITDA Margin is -56.1%, based on as-reported figures from SEC (XBRL) filings.